Imperial College London

DrJustineReise

Faculty of MedicineSchool of Public Health

Head of Operations
 
 
 
//

Contact

 

+44 (0)20 7594 5275j.reise Website

 
 
//

Location

 

Stadium HouseWhite City

//

Summary

 

Publications

Publication Type
Year
to

15 results found

Coombes RC, Tat T, Miller ML, Reise JA, Mansi JL, Hadjiminas DJ, Shousha S, Elsheikh SE, Lam EW-F, Horimoto Y, El-Bahrawy M, Aboagye EO, Contractor KB, Shaw JA, Walker RA, Marconell MH, Palmieri C, Stebbing Jet al., 2013, An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study), ANNALS OF ONCOLOGY, Vol: 24, Pages: 924-930, ISSN: 0923-7534

JOURNAL ARTICLE

Stebbing J, Payne R, Reise J, Frampton AE, Avery M, Woodley L, Di Leo A, Pestrin M, Krell J, Coombes RCet al., 2013, The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study, PLOS ONE, Vol: 8, ISSN: 1932-6203

JOURNAL ARTICLE

Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJH, Lonning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RCet al., 2012, Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study, JOURNAL OF CLINICAL ONCOLOGY, Vol: 30, Pages: 709-717, ISSN: 0732-183X

JOURNAL ARTICLE

Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MWK, Reise JA, Wilkinson K, Hupperets Pet al., 2011, Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer, JOURNAL OF CLINICAL ONCOLOGY, Vol: 29, Pages: 3247-3254, ISSN: 0732-183X

JOURNAL ARTICLE

Coombes RC, Reise JA, Lau M, Carme SC, Searle GE, Huiban M, Burgess P, Koch K, Das-Gupta A, Saleem Aet al., 2011, An open-label positron emission tomography (PET) study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing (HER2+) advanced or metastatic breast cancer (MBC)., JOURNAL OF CLINICAL ONCOLOGY, Vol: 29, ISSN: 0732-183X

JOURNAL ARTICLE

Coombes RC, Reise JA, Lau M, Carme SC, Searle GE, Huiban M, Burgess P, Koch K, Das-Gupta A, Saleem Aet al., 2011, An open-label positron emission tomography (PET) study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing (HER2+) advanced or metastatic breast cancer (MBC)., J Clin Oncol, Vol: 29

TPS107 Background: Patients with HER2+ breast cancer tend to develop visceral metastases. Several anti-cancer agents including trastuzumab are not believed to readily cross the blood-brain barrier (BBB); hence, central nervous system (CNS) disease progression is emerging as an important clinical problem in this patient population. Although preclinical data suggest that lapatinib brain concentrations are low in healthy animals, probably due to the BBB efflux transporters, observations from clinical studies suggest lapatinib treatment might be associated with reduced CNS tumor growth. One hypothesis is that disruption of the BBB by tumors circumvents the usual protective function of transporters or that inhibition of efflux transporters by lapatinib enhances accumulation upon repeat dosing. The role of lapatinib in prevention of brain metastases is currently explored in a Phase III trial, EGF 111438 (CEREBREL). METHODS: In order to directly assess if lapatinib penetrates into the brain and brain metastases, an open-label, non-randomized study using carbon-11 labeled [(11)C] lapatinib is performed in patients with HER2+ MBC. A minimum of 10 patients with an ECOG of < 3 into two cohorts: (a) with at least one 1 cm diameter brain metastasis or (b) without brain metastases. Two PET scans are performed in each pt following intravenous administration of a microdose of [(11)C] lapatinib - (1) in lapatinib -naïve patients and (2) at steady state lapatinib, after treatment with unlabelled oral lapatinib 1500mg OD for 8 days. [(11)C] lapatinib time-activity curves are generated for normal brain and brain metastases, the PET volume of distribution in brain calculated and penetration of [(11)C] lapatinib into brain quantified. Analysis of brain PET data is explorative as [(11)C] lapatinib is a new tracer. Therefore, this study investigates both the difference in lapatinib brain penetration between patients with and without brain metastases, as well as the effect of low an

JOURNAL ARTICLE

Coombes RC, Reise JA, Lau MR, Carme SC, Searle GE, Huiban M, Burgess P, Noibi S, Koch K, Sapunar F, Saleem Aet al., 2011, An Open-Label Positron Emission Tomography Study To Investigate and Quantify Brain and Tumor Penetration of Carbon 11-Labeled Lapatinib in Patients with HER2-Overexpressing Advanced or Metastatic Breast Cancer., CANCER RESEARCH, Vol: 71, ISSN: 0008-5472

JOURNAL ARTICLE

Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals JJ, Tres A, Coleman RE, Reise J, Cooper D, Hupperets Pet al., 2010, DEVA: Randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients., JOURNAL OF CLINICAL ONCOLOGY, Vol: 28, ISSN: 0732-183X

JOURNAL ARTICLE

Reise JA, Sheldon H, Earnshaw J, Naylor AR, Dick F, Powell JT, Greenhalgh RMet al., 2010, Patient Preference for Surgical Method of Abdominal Aortic Aneurysm Repair: Postal Survey, EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, Vol: 39, Pages: 55-61, ISSN: 1078-5884

JOURNAL ARTICLE

Dick F, Brown LC, Powell JT, Reise J, Greenhalgh RMet al., 2008, Appraisal era for endovascular repair of abdominal aortic aneurysms, ACTA CHIRURGICA BELGICA, Vol: 108, Pages: 288-291, ISSN: 0001-5458

JOURNAL ARTICLE

Bayston T, Ramessur S, Reise J, Jones KG, Powell JTet al., 2003, Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells., J Vasc Surg, Vol: 38, Pages: 354-359

JOURNAL ARTICLE

Bayston T, Ramessur S, Reise J, Jones KG, Powell JTet al., 2003, Prostaglandin E-2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells, JOURNAL OF VASCULAR SURGERY, Vol: 38, Pages: 354-359, ISSN: 0741-5214

JOURNAL ARTICLE

Jones KG, Reise J, Greenhalgh RM, Powell JTet al., 2002, Regulation of interleukin 6 production by abdominal aortic aneurysms, BRITISH JOURNAL OF SURGERY, Vol: 89, Pages: 659-659, ISSN: 0007-1323

JOURNAL ARTICLE

Reise JA, Taylor GW, Fardy CH, Silverman Met al., 1997, Glutathione and neonatal lung disease, CLINICA CHIMICA ACTA, Vol: 265, Pages: 113-119, ISSN: 0009-8981

JOURNAL ARTICLE

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00164867&limit=30&person=true